查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1848727

医院感染控制市场（按产品类型和应用）—全球预测 2025-2032

Hospital Acquired Infection Control Market by Product Type, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，医院感染控制市场规模将成长至 612 亿美元，复合年增长率为 6.71%。

主要市场统计数据
基准年2024年 363.9亿美元
预计2025年 387.9亿美元
预测年份：2032年 612亿美元
复合年增长率（%） 6.71%

权威概述，为现代感染预防策略建立背景，涵盖技术、临床环境和供应链弹性

院内感染仍然是对病人安全、临床结果和医疗机构声誉的持续威胁。病原体谱的演变、监管审查的加强以及对机构层面復原力的不断提升的期望，使得感染预防成为临床和营运策略的核心。本简介从多方面概述了感染控制技术和临床应用，为深入分析产品类别、护理环境和地理动态奠定了基础。

当今产业的特点是技术创新快速发展、跨部门协作和供应链审查日益严格。空气净化技术、抗生素涂层、手部卫生配方、器械灭菌平台、表面消毒剂、紫外线系统和水处理流程等创新技术正在整合到更广泛的感染预防项目中。同时，医疗保健服务模式正转向跨设施的护理，例如急诊科、综合医院病房、加护病房、手术室和门诊病人设施，每个设施都有不同的感染控制要求和营运限制。这些相互交织的趋势要求我们采取整合策略策略，将工程控制、表面和器械消毒以及行为导向的合规计划相结合。

随着相关人员寻求降低感染发生率的切实可行的途径，本导言将帮助读者了解影响采购、临床政策和资本规划的关键考量。本导言也确立了后续章节中使用的分析视角——重点关注技术有效性、临床适用性、监管合规性和供应链弹性——以指导基于证据的感染控制解决方案的采用和推广。

技术创新、临床工作流程重新设计和监管期望的融合如何重塑整个医疗环境中的感染预防

在技​​术进步、监管趋势和临床工作流程转变的推动下，感染预防领域正在经历一系列变革时期。空气管理创新正从单一用途的过滤转向整合系统，该系统结合了高效能空气微粒子过滤器 (HEPA)过滤、电离技术和针对性紫外线空气处理技术，以减少高风险区域的气溶胶病原体含量。表面和设备消毒方法如今结合了成熟的化学方法，包括醇基和氯基消毒剂、过氧化氢化合物、季铵盐製剂以及汽化过氧化氢和低温系统等先进的灭菌方法，以构建互补的多层防御体系。

从黏性导管到银基表面等留置设备上的抗菌涂层，以及抗菌管理，正在重新评估，以平衡设备相关感染的减少和抗药性考虑。手部卫生解决方案已多样化，包括含酒精的凝胶、泡沫和液体，以及抗菌肥皂和一次性擦拭巾，并提供根据工作流程和合规性量身定制的交付形式。紫外线消毒系统已发展成为固定装置和便携式设备，支援有针对性的设备清洁和快速的房间週转；水处理解决方案现已整合化学剂量、过滤和紫外线处理，以应对管道相关风险。

加护治疗和手术室的诊疗方案正日益以实证医学主导，并日益仪器化，而急诊和门诊设施则需要快速、可扩展且不影响诊疗效率的干预措施。这些发展正在重塑采购优先事项、资金配置和临床实践指南，并促进临床团队、设施管理人员和技术提供者之间建立新的合作关係。

评估 2025 年关税变化对感染控制设备采购、供应链弹性和临床连续性的下游营运和采购影响

2025年实施的关税和贸易政策调整，正在对感染预防技术​​供应链、筹资策略和资本规划产生连锁反应。关税相关的成本压力正在影响关键投入的采购，例如高效空气过滤器 (HEPA) 系统的过滤介质、涂层设备中使用的特种聚合物以及紫外线消毒设备的组件，促使采购团队重新评估其供应商组合，并考虑近岸外包和多元化策略，以保持供应的连续性。

为此，许多医疗保健系统和製造商正在进行全面的供应链风险评估，并调整合约条款，以纳入紧急条款、替代采购路径以及检验任务物品的策略性库存缓衝。不断变化的成本动态也影响了进口成品与国产替代品的相对竞争力，推动了对灭菌设备、消毒配方和耗材的国内生产能力的投资。对经过验证的灭菌製程和产品性能的监管要求进一步加剧了快速更换供应商的复杂性，促使跨职能团队在合规需求和成本控制之间取得平衡。

在临床上，这些交易动态促使企业对整体拥有成本（包括耐用性、维护要求和耗材消耗模式）进行更严格的评估，而非仅依赖单价。采购和临床领导者越来越重视与能够提供服务、培训和检验的性能数据的供应商建立伙伴关係，以降低营运风险。因此，关税主导的压力正在加速企业向更具弹性、更多样化的供应链以及临床、采购和製造相关人员之间更紧密合作的策略调整。

透过细分洞察，为采购和部署策略提供资讯，将特定的感染控制产品类别与不同的临床环境和操作限制联繫起来

要深入了解需求驱动因素，需要按产品类型和临床应用进行细分，因为这些维度的交集决定了临床效用、采购优先顺序和采用路径。按产品划分，空气净化技术包括基于 HEPA 过滤器的系统、电离平台和紫外线增强空气清净器，每种技术都提供与减轻空气传播病原体相关的独特性能特征。抗菌涂层，无论是黏合到导管表面或银基涂层，都旨在降低与器械相关的感染风险，但必须评估其与器械材料的兼容性和抗菌管理问题。手部卫生解决方案包括以凝胶、泡沫或液体形式提供的酒精类消毒剂、抗菌肥皂和一次性湿纸巾，其选择受工作流程、皮肤耐受性和依从性指标的影响。器械灭菌选项包括蒸气、环氧乙烷、辐射、低温和汽化过氧化氢系统，需要在週期时间、材料相容性和吞吐量之间进行权衡。表面消毒剂包括醇基、氯基、过氧化物基和季铵盐基，每种消毒剂都适用于特定的表面类型和接触时间要求。紫外线消毒解决方案有固定式和携带式形式，每种形式都支援不同的操作模式。同时，水处理策略结合了化学投加、过滤和紫外线处理，以解决管道相关的感染媒介。

此外，水处理策略透过结合化学剂量和紫外线处理来解决与管道相关的感染媒介。急诊需要能够在成人和儿科护理区域提供强大病原体控制的同时保持快速患者流量的解决方案。内科、整形外科和外科病房需要可扩展的干预措施，并与常规内科和护理工作流程相结合。加护病房护病房涵盖成人、新生儿和小儿科专科，由于病患的脆弱性和侵入性器械的普遍性，需要最高水准的器械和环境控制。手术室需要协调一致的术中、术前和术后方法，优先考虑无菌和轮转效率。门诊设施，例如门诊手术中心和诊所，需要感染预防技术​​，以平衡成本效益和法规遵循并提高患者吞吐量。透过选择针对每个医疗环境细微差别的产品，医疗机构可以实现既能反映临床需求又能反映营运现实的性能。

影响全球主要医疗保健市场技术选择、监管协调和支援模式的区域动态和采用模式

区域动态塑造感染预防解决方案的法规环境、技术采用曲线和供应链路径。在美洲，法律规范和报销模式激励医疗相关感染的显着减少，推动了对有效灭菌平台、先进空气管理系统和强大手部卫生计画的需求。在该地区运营的製造商通常强调服务网络、培训和检验的性能数据，以支援在急诊和门诊环境中的应用。同时，欧洲、中东和非洲是一个多元化的地区，监管环境因司法管辖区而异，某些市场的基础设施差距为可携式紫外线设备、水处理套件和可扩展的消毒化学品创造了机会，这些设备无需大量资本投入即可部署。与当地经销商的伙伴关係以及适应不同的临床工作流程是这些市场成功的关键因素。

亚太地区城市中心的技术应用正在快速发展，而周边医疗环境的医疗能力却参差不齐。该地区规模较大的手术中心和三级医院正在采用整合式器械灭菌技术、抗生素涂层器械和集中式空气处理升级，而规模较小的医疗机构则通常优先考虑经济高效的手部卫生解决方案、可携式紫外线设备和模组化水处理设备。在所有地区，供应链的弹性、是否符合当地法规以及是否拥有训练有素的服务技术人员仍然是影响采购决策的关键考虑因素。了解区域差异有助于相关人员製化产品、支援模式和培训计划，以满足全球医疗保健系统的不同需求。

製造商、配方师和服务供应商之间的竞争与合作在确定产品性能、采购吸引力和长期临床结果方面的作用

要成功驾驭感染预防市场，需要了解不同类型公司（从设备製造商到配方商再到服务供应商）的角色和能力。设计空气净化系统、紫外线设备和灭菌平台的技术供应商在工程性能、检验数据和服务生态系统方面竞争，而消毒剂和手部卫生产品的配方商则必须在功效、材料相容性和皮肤耐受性之间取得平衡。专注于抗菌涂层和设备整合抗菌技术的公司处于材料科学和监管监督的交叉领域，需要强大的生物相容性和抗药性管理策略。

不仅是产品开发商，而且提供安装、维护和验证服务的人员也在持续的临床表现中发挥关键作用。提供预防性保养、快速维修和性能检验的服务型公司可以减少停机时间并保持感染控制的有效性。同样，经销商和物流合作伙伴对于维持过滤器、灭菌浓缩液和消毒剂填充用等耗材的稳定供应至关重要。设备製造商、製剂製造商和服务网路之间的策略联盟和伙伴关係日益普遍，从而实现了捆绑销售，简化了采购并协调了绩效激励。投资者和企业策略家也关注那些表现出强大上市后监测能力和支持奖励研究以证明真实世界疗效的公司。

为医疗保健和行业领导者提供切实可行的优先行动，以加强感染预防绩效、供应链弹性和可衡量的临床结果

行业领导者可以采取具体措施，将洞察转化为更安全的医疗保健和营运韧性。首先，协调检验标准，考虑经过验证的绩效指标和总拥有成本，以确保所选技术能持续提供临床效益，且不会造成过度的营运负担。其次，投资服务合约和本地技术能力，以最大限度地减少灭菌设备、空气处理系统和紫外线设备的停机时间，并确保及时补充耗材。第三，采用综合感染预防策略，将工程控制、表面和器械消毒以及以行为为中心的干预措施（例如手部卫生培训和合规性监测）相结合，以实现纵深防御。

此外，为了减轻贸易政策变化和零件短缺的影响，我们优先考虑供应商多元化和供应链透明度，并参与情境规划以检验紧急方案。我们促进临床工程合作，在具代表性的临床环境中试行新技术，并收集可操作的绩效数据，为更广泛的部署提供参考。最后，我们建立采购合同，纳入可衡量的绩效保证、培训和实施后评估，使供应商奖励与临床结果一致。这些建议旨在适用于各种规模和资源环境的组织，使领导者能够做出明智的权衡，并部署能够带来持续、可衡量价值的感染预防投资。

结合现场访谈、临床观察、文献综合和供应链分析的透明、多方法研究途径检验了可操作的发现

本执行摘要所依据的研究整合了定性和定量方法，以确保研究的稳健性和有效性。主要研究包括对感染预防负责人、设施经理、采购专业人员以及急诊和门诊护理机构的临床专家进行结构化访谈，以及实地考察，以观察技术整合、工作流程影响和维护实践。次要研究则查阅了关于设备灭菌方法、消毒剂化学成分、空气品管和临床指南的同行评审文献，以基于既定证据提供产品级评估。

影响分析方法将比较技术评估框架（用于评估有效性、相容性和营运影响）与供应链风险分析相结合，以绘製采购漏洞图并制定缓解策略。細項分析利用产品和应用分类法来评估医疗环境中的适用部署方案。与临床和工程专家进行了交叉检验研讨会，以完善解读，并确保建议在现实约束条件下切实可行。最后，对不同资料来源的研究结果进行三角测量，以减少偏差，并突出能够更好地为决策提供资讯的趋同主题。

整合和策略要务强调综合防御、跨部门合作和持续的商业投资，以降低感染风险

最后，感染预防领域正处于曲折点，技术成熟度、临床实践的演变以及供应链的现实状况既带来了挑战，也带来了机会。整合净化空气、有效的表面和器械消毒、抗生素涂层器械策略以及行为指导式手部卫生方案的多层防御体系，能够为预防医疗相关感染提供最强大的防御。要实施这样的防御体系，需要将产品功能与急诊科、综合医院病房、加护病房、手术室和门诊病人设施的具体需求进行仔细匹配，并密切关注供应链在政策和贸易变化下的韧性。

相关人员若能采取实证主导的跨职能方法，将临床负责人、设备工程师、采购负责人和值得信赖的服务合作伙伴聚集在一起，最有能力在病人安全方面取得显着的改善。持续投资于培训、绩效检验和实施后评估，可以长期维持改善。这项结论强调，需要采取果断行动、务实投资并建立合作伙伴关係，以持续降低感染风险并提高整体医疗品质。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 日益增长的认知度和已证实的有效性推动了紫外线消毒技术在医疗环境中的广泛应用
  • 整合人工智慧预测分析，识别高风险患者，制定针对性的感染预防策略
  • 开发抗菌铜和银涂层表面，以减少频繁接触区域的病原体传播
  • 增加一次性医疗设备的使用，以最大限度地减少交叉污染并简化灭菌工作流程
  • 实施即时病患监测平台，以便及早发现感染指标并缩短反应时间
  • 加强监管和严格医院病原体报告要求推动感染控制投资
  • 抗菌涂料与智慧感测器结合的需求不断增长，可持续监测卫生合规性
  • 用于远端感染监测和住院患者出院后监测的新兴远端医疗解决方案

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章：医院感染控制市场（依产品类型）

  • 空气清净系统
    • HEPA 过滤器
    • 电离系统
    • 紫外线空气清净机
  • 抗生素涂层
    • 黏合导管
    • 银涂层
  • 手部卫生产品
    • 酒精消毒剂
      • 形式
      • 凝胶
      • 液体
    • 抗菌肥皂
    • 擦拭巾
  • 器械消毒器
    • 环氧乙烷灭菌器
    • 巴氏杀菌机
    • 放射线杀菌
    • 蒸气灭菌器
    • 过氧化氢蒸气灭菌器
  • 表面消毒剂
    • 酒精消毒剂
    • 氯基消毒剂
    • 过氧化物
    • 季铵化合物
  • 紫外线消毒系统
    • 固定紫外线系统
    • 可携式紫外线设备
  • 水处理系统
    • 化学处理
    • 过滤系统
    • 紫外线水处理

第九章医院感染控制市场（按应用）

  • 急诊部
    • 成人紧急状况
    • 儿科急救
  • 普通病房
    • 内科病房
    • 整形外科病房
    • 外科病房
  • 加护病房
    • 成人加护病房
    • 新生儿加护病房
    • 加护病房
  • 手术室
    • 手术期间
    • 术后
    • 术前
  • 门诊设施
    • 门诊手术中心
    • 诊所

第 10 章：按地区分類的医院感染控制市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第11章医院感染控制市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 12 章：按国家分類的医院感染控制市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十三章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Ecolab Inc.
    • 3M Company
    • Danaher Corporation
    • STERIS plc
    • Getinge AB
    • Johnson & Johnson
    • Cardinal Health, Inc.
    • B. Braun Melsungen AG
    • Molnlycke Health Care AB
    • Ansell Limited
Product Code: MRR-035590447FE4

The Hospital Acquired Infection Control Market is projected to grow by USD 61.20 billion at a CAGR of 6.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 36.39 billion
Estimated Year [2025] USD 38.79 billion
Forecast Year [2032] USD 61.20 billion
CAGR (%) 6.71%

An authoritative overview establishing the context for modern infection prevention strategies across technologies, clinical settings, and supply chain resilience

Healthcare-acquired infections remain a persistent threat to patient safety, clinical outcomes, and institutional reputation. The convergence of evolving pathogen profiles, tighter regulatory scrutiny, and heightened expectations for facility-level resilience has placed infection prevention at the center of clinical and operational strategy. This introduction frames the multi-dimensional landscape of infection control technologies and clinical applications, setting the stage for deeper analysis across product classes, care settings, and regional dynamics.

The industry today is characterized by rapid technological iteration, cross-disciplinary collaboration, and increased scrutiny of supply chains. Innovations spanning air purification technologies, antibiotic coatings, hand hygiene formulations, instrument sterilization platforms, surface disinfectants, ultraviolet systems, and water treatment processes are being integrated into broader infection prevention programs. Concurrently, healthcare delivery models are shifting care across emergency departments, general wards, intensive care units, operating rooms, and outpatient facilities, each with distinct infection control requirements and operational constraints. These intersecting trends demand integrated strategies that combine engineering controls, surface and instrument decontamination, and behaviorally informed compliance programs.

As stakeholders seek pragmatic pathways to reduce infection incidence, the introduction grounds the reader in the essential considerations that shape procurement, clinical policy, and capital planning. It also establishes the analytical lens used across subsequent sections: a focus on technological efficacy, clinical fit, regulatory alignment, and supply chain resilience to inform evidence-based adoption and scale-up of infection control solutions.

How converging technological innovations, clinical workflow redesigns, and regulatory expectations are reshaping infection prevention across healthcare environments

The infection prevention landscape is undergoing a series of transformative shifts driven by technological advances, regulatory pressures, and changing clinical workflows. Innovations in air management have moved beyond single-purpose filtration to integrated systems that combine HEPA filtration, ionization technologies, and targeted UV air treatment to reduce aerosolized pathogen loads in high-risk areas. Surface and instrument decontamination approaches now pair proven chemistries such as alcohol and chlorine-based disinfectants with peroxygen compounds, quaternary ammonium formulations, and advanced sterilization modalities including vaporized hydrogen peroxide and low-temperature systems, creating layered defenses that complement one another.

Antibiotic coatings for indwelling devices, spanning bonded catheters to silver-based surfaces, are being reevaluated alongside antimicrobial stewardship to balance device-associated infection reduction with resistance considerations. Hand hygiene solutions have diversified to include alcohol-based gels, foams, and liquids alongside antimicrobial soaps and single-use wipes, with delivery formats tailored to workflow and compliance. Ultraviolet disinfection systems have matured into fixed installations and portable devices that support targeted terminal cleaning and rapid room turnover, while water treatment solutions now integrate chemical dosing, filtration, and ultraviolet treatment to address plumbing-related risks.

These technological shifts coincide with operational realignments: intensive care and operating room protocols are increasingly evidence-driven and instrumented, whereas emergency departments and outpatient facilities require rapid, scalable interventions that do not impede throughput. Collectively, these developments are reshaping procurement priorities, capital allocation, and clinical practice guidelines, and they are prompting new collaborations between clinical teams, facilities management, and technology providers.

Assessing the downstream operational and procurement consequences of 2025 tariff shifts on infection control equipment sourcing, supply chain resilience, and clinical continuity

The introduction of tariffs and trade policy adjustments in 2025 has had a cascading effect on supply chains, procurement strategies, and capital planning for infection prevention technologies. Tariff-related cost pressures have influenced the sourcing of critical inputs such as filtration media for HEPA systems, specialized polymers used in coated devices, and components for ultraviolet disinfection equipment, prompting procurement teams to reassess supplier portfolios and consider nearshoring or diversification strategies to maintain continuity of supply.

In response, many health systems and manufacturers have undertaken comprehensive supply chain risk assessments and have adjusted contractual terms to include contingency clauses, alternative sourcing pathways, and strategic inventory buffers for mission-critical items. The shifting cost dynamics have also influenced the relative competitiveness of imported finished goods versus domestically produced alternatives, catalyzing investment in local manufacturing capacity for sterilization equipment, disinfectant formulation, and consumables. Regulatory requirements for validated sterilization processes and product performance have further complicated rapid supplier substitution, motivating cross-functional teams to balance compliance needs with cost containment.

Clinically, these trade dynamics have driven more rigorous evaluation of total cost of ownership, including durability, maintenance requirements, and consumable consumption patterns, rather than relying solely on unit price. Procurement and clinical leaders have increasingly prioritized supplier partnerships that offer service, training, and validated performance data to mitigate operational risk. As a result, tariff-driven pressures have accelerated strategic realignment toward resilient, diversified supply chains and closer collaboration between clinical, procurement, and manufacturing stakeholders.

Segmented insights linking specific infection control product classes to diverse clinical environments and operational constraints to inform procurement and deployment strategies

A nuanced understanding of demand drivers requires segmentation by product type and by clinical application, because the intersection of these dimensions determines clinical utility, procurement priorities, and implementation pathways. Product-wise, air purification technologies encompass HEPA filter-based systems, ionization platforms, and UV-enhanced air purifiers, each offering distinct performance characteristics relevant to airborne pathogen mitigation. Antibiotic coatings, whether applied as bonded catheter surfaces or silver-based finishes, are engineered to reduce device-associated infection risk but must be evaluated for compatibility with device materials and antimicrobial stewardship concerns. Hand hygiene solutions range from alcohol-based sanitizers delivered as gel, foam, or liquid to antimicrobial soaps and single-use hand wipes, with selection influenced by workflow, skin tolerance, and compliance metrics. Instrument sterilization options span steam, ethylene oxide, radiation, low-temperature, and vaporized hydrogen peroxide systems, creating trade-offs between cycle time, material compatibility, and throughput. Surface disinfectants include alcohol and chlorine chemistries, peroxygen compounds, and quaternary ammonium formulations, each suited to specific surface types and contact-time requirements. Ultraviolet disinfection solutions are available as fixed installations and portable devices that serve different operational models, while water treatment strategies combine chemical dosing, filtration, and ultraviolet treatment to address plumbing-related infection vectors.

Application-wise, distinct clinical settings present differentiated requirements and constraints. Emergency departments require solutions that maintain rapid patient flow while providing robust pathogen control across adult and pediatric care areas. General wards, including medical, orthopedic, and surgical units, need scalable interventions that integrate with routine housekeeping and nursing workflows. Intensive care units, covering adult, neonatal, and pediatric subspecialties, demand the highest levels of instrument and environmental control due to patient vulnerability and invasive device prevalence. Operating rooms require coordinated intraoperative, preoperative, and postoperative approaches that prioritize sterility and turnover efficiency. Outpatient facilities, such as ambulatory surgical centers and clinics, seek infection prevention technologies that balance cost-effectiveness with regulatory compliance and high patient throughput. By aligning product selection with the nuances of each care setting, healthcare organizations can achieve performance outcomes that reflect both clinical needs and operational realities.

Regional dynamics and adoption patterns that influence technology selection, regulatory alignment, and support models across major global healthcare markets

Regional dynamics shape the regulatory environment, technology adoption curves, and supply chain pathways for infection prevention solutions. In the Americas, regulatory frameworks and reimbursement models incentivize measurable reductions in healthcare-acquired infections, driving demand for validated sterilization platforms, advanced air management systems, and robust hand hygiene programs. Manufacturers active in this region often emphasize service networks, training, and validated performance data to support adoption across acute and ambulatory settings. Meanwhile, Europe, Middle East & Africa present a heterogeneous landscape where regulatory standards vary across jurisdictions, and infrastructure gaps in some markets create opportunities for portable ultraviolet devices, water treatment packages, and scalable disinfection chemistries that can be deployed without extensive capital works. In these markets, partnerships with local distributors and adaptation to diverse clinical workflows are critical success factors.

Asia-Pacific demonstrates rapid technology uptake in urban centers alongside varied capacity in peripheral healthcare settings. High-volume surgical centers and tertiary hospitals in the region have embraced integrated instrument sterilization technologies, antibiotic-coated devices, and centralized air-handling upgrades, while smaller facilities often prioritize cost-effective hand hygiene solutions, portable UV devices, and modular water treatment units. Across all regions, supply chain resilience, local regulatory alignment, and the availability of trained service technicians remain pivotal considerations that influence procurement decisions. Understanding regional variations enables stakeholders to tailor offerings, support models, and training programs that meet the distinct needs of healthcare systems around the world.

Competitive and collaborative roles of manufacturers, formulators, and service providers that determine product performance, procurement appeal, and long-term clinical outcomes

Successful navigation of the infection prevention market requires an appreciation of the roles and capabilities of different types of companies, from equipment manufacturers to formulators and service providers. Technology vendors that design air purification systems, ultraviolet devices, and sterilization platforms compete on engineering performance, validation data, and service ecosystems, while formulators of disinfectants and hand hygiene products must balance efficacy, material compatibility, and skin tolerability. Companies specializing in antibiotic coatings and device-integrated antimicrobial technologies operate at the intersection of materials science and regulatory scrutiny, requiring robust biocompatibility and resistance management strategies.

Beyond product developers, companies providing installation, maintenance, and validation services play an outsized role in sustained clinical performance. Service-oriented firms that offer preventive maintenance, rapid repair, and performance verification reduce downtime and preserve infection control efficacy. Similarly, distributors and logistics partners are critical to maintaining steady supplies of consumables such as filters, sterilization wrap, disinfectant concentrates, and sanitizer refills. Strategic collaborations and partnerships between device makers, formulators, and service networks are increasingly common, enabling bundled offerings that simplify procurement and align incentives around performance. Investors and corporate strategists are also focusing on companies that demonstrate strong post-market surveillance capabilities and the ability to support clinical studies that substantiate real-world effectiveness.

Practical and prioritized actions for healthcare and industry leaders to enhance infection prevention performance, supply chain resilience, and measurable clinical outcomes

Industry leaders can take concrete steps to translate insights into safer care and operational resilience. First, align procurement criteria with validated performance metrics and total cost of ownership considerations to ensure that chosen technologies deliver sustained clinical benefits without imposing undue operational burden. Second, invest in service agreements and local technical capacity to minimize downtime for sterilization equipment, air handling systems, and ultraviolet devices, and to ensure consumables are replenished promptly. Third, adopt an integrated infection prevention strategy that blends engineering controls, surface and instrument decontamination, and behavior-focused interventions such as hand hygiene training and compliance monitoring to achieve multilayered protection.

Additionally, prioritize supplier diversification and supply chain transparency to mitigate the effects of trade policy shifts and component shortages, and engage in scenario planning to validate contingency options. Foster clinical-engineering collaboration to pilot new technologies in representative care settings, collecting pragmatic performance data that inform broader rollouts. Finally, structure procurement contracts to include measurable performance guarantees, training, and post-implementation evaluation to align vendor incentives with clinical outcomes. These recommendations are designed to be actionable across a range of organizational sizes and resource environments, enabling leaders to make informed trade-offs and to deploy infection prevention investments that deliver consistent, measurable value.

A transparent, multi-method research approach combining field interviews, clinical observation, literature synthesis, and supply chain analysis to validate actionable findings

The research underpinning this executive summary integrates qualitative and quantitative approaches to ensure robustness and relevance. Primary research included structured interviews with infection prevention leaders, facilities managers, procurement professionals, and clinical specialists across acute and ambulatory care settings, supplemented by site visits to observe technology integration, workflow impacts, and maintenance practices. Secondary research reviewed peer-reviewed literature on device sterilization methods, disinfection chemistries, air quality control, and clinical guidelines to ground product-level assessments in established evidence.

Analytical methods combined comparative technology evaluation frameworks, which assess efficacy, compatibility, and operational impact, with supply chain risk analysis to map sourcing vulnerabilities and mitigation strategies. Segmentation analysis drew from product and application taxonomies to evaluate fit-for-purpose deployment scenarios across care settings. Peer validation workshops were conducted with clinical and engineering subject matter experts to refine interpretations and ensure that recommendations are practicable within real-world constraints. Finally, findings were triangulated across data sources to reduce bias and to highlight convergent themes that reliably inform decision-making.

Synthesis and strategic imperatives emphasizing integrated defenses, cross-functional collaboration, and sustained operational investment to reduce infection risk

In closing, the infection prevention landscape is at an inflection point where technological maturity, clinical practice evolution, and supply chain realities converge to create both challenges and opportunities. Layered defenses that integrate air purification, validated surface and instrument decontamination, antibiotic-coated device strategies, and behaviorally informed hand hygiene programs offer the most robust protection against healthcare-acquired infections. Operationalizing these defenses requires careful alignment of product capabilities with the specific demands of emergency departments, general wards, intensive care units, operating rooms, and outpatient facilities, and it necessitates vigilant attention to supply chain resilience in the face of policy and trade shifts.

Stakeholders who adopt an evidence-driven, cross-functional approach-bringing together clinical leadership, facilities engineering, procurement, and trusted service partners-will be best positioned to deliver measurable improvements in patient safety. Continued investment in training, performance verification, and post-implementation evaluation will sustain gains over time. The conclusion underscores the imperative for decisive action, pragmatic investment, and collaborative partnerships to realize durable reductions in infection risk and to enhance overall healthcare quality.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of UV disinfection technology adoption in healthcare settings due to increased awareness and proven efficacy
  • 5.2. Integration of AI-driven predictive analytics to identify high-risk patients for targeted infection prevention strategies
  • 5.3. Development of antimicrobial copper and silver-coated surfaces to reduce pathogen transmission on high-touch areas
  • 5.4. Rise of single-use disposable medical devices to minimize cross-contamination and streamline sterilization workflows
  • 5.5. Implementation of real-time patient monitoring platforms for early detection of infection indicators and improved response times
  • 5.6. Increased regulatory scrutiny and stricter reporting requirements for hospital pathogens driving infection control investments
  • 5.7. Growing demand for combined antimicrobial coatings and smart sensors to continuously monitor hygiene compliance
  • 5.8. Emergence of telemedicine solutions for remote infection surveillance and post-discharge monitoring of hospital patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hospital Acquired Infection Control Market, by Product Type

  • 8.1. Air Purification Systems
    • 8.1.1. HEPA Filters
    • 8.1.2. Ionization Systems
    • 8.1.3. UV Air Purifiers
  • 8.2. Antibiotic Coatings
    • 8.2.1. Bonded Catheters
    • 8.2.2. Silver Coatings
  • 8.3. Hand Hygiene Products
    • 8.3.1. Alcohol Based Sanitizers
      • 8.3.1.1. Foam
      • 8.3.1.2. Gel
      • 8.3.1.3. Liquid
    • 8.3.2. Antimicrobial Soaps
    • 8.3.3. Hand Wipes
  • 8.4. Instrument Sterilization Equipment
    • 8.4.1. Ethylene Oxide Sterilizers
    • 8.4.2. Low Temperature Sterilizers
    • 8.4.3. Radiation Sterilizers
    • 8.4.4. Steam Sterilizers
    • 8.4.5. Vaporized Hydrogen Peroxide Sterilizers
  • 8.5. Surface Disinfectants
    • 8.5.1. Alcohol Based Disinfectants
    • 8.5.2. Chlorine Based Disinfectants
    • 8.5.3. Peroxygen Compounds
    • 8.5.4. Quaternary Ammonium Compounds
  • 8.6. Ultraviolet Disinfection Systems
    • 8.6.1. Fixed UV Systems
    • 8.6.2. Portable UV Devices
  • 8.7. Water Treatment Systems
    • 8.7.1. Chemical Treatment
    • 8.7.2. Filtration Systems
    • 8.7.3. UV Water Treatment

9. Hospital Acquired Infection Control Market, by Application

  • 9.1. Emergency Departments
    • 9.1.1. Adult Emergency
    • 9.1.2. Pediatric Emergency
  • 9.2. General Wards
    • 9.2.1. Medical Wards
    • 9.2.2. Orthopedic Wards
    • 9.2.3. Surgical Wards
  • 9.3. Intensive Care Units
    • 9.3.1. Adult ICU
    • 9.3.2. Neonatal ICU
    • 9.3.3. Pediatric ICU
  • 9.4. Operating Rooms
    • 9.4.1. Intraoperative
    • 9.4.2. Postoperative
    • 9.4.3. Preoperative
  • 9.5. Outpatient Facilities
    • 9.5.1. Ambulatory Surgical Centers
    • 9.5.2. Clinics

10. Hospital Acquired Infection Control Market, by Region

  • 10.1. Americas
    • 10.1.1. North America
    • 10.1.2. Latin America
  • 10.2. Europe, Middle East & Africa
    • 10.2.1. Europe
    • 10.2.2. Middle East
    • 10.2.3. Africa
  • 10.3. Asia-Pacific

11. Hospital Acquired Infection Control Market, by Group

  • 11.1. ASEAN
  • 11.2. GCC
  • 11.3. European Union
  • 11.4. BRICS
  • 11.5. G7
  • 11.6. NATO

12. Hospital Acquired Infection Control Market, by Country

  • 12.1. United States
  • 12.2. Canada
  • 12.3. Mexico
  • 12.4. Brazil
  • 12.5. United Kingdom
  • 12.6. Germany
  • 12.7. France
  • 12.8. Russia
  • 12.9. Italy
  • 12.10. Spain
  • 12.11. China
  • 12.12. India
  • 12.13. Japan
  • 12.14. Australia
  • 12.15. South Korea

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Analysis
    • 13.3.1. Ecolab Inc.
    • 13.3.2. 3M Company
    • 13.3.3. Danaher Corporation
    • 13.3.4. STERIS plc
    • 13.3.5. Getinge AB
    • 13.3.6. Johnson & Johnson
    • 13.3.7. Cardinal Health, Inc.
    • 13.3.8. B. Braun Melsungen AG
    • 13.3.9. Molnlycke Health Care AB
    • 13.3.10. Ansell Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. AMERICAS HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. NORTH AMERICA HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. LATIN AMERICA HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. EUROPE, MIDDLE EAST & AFRICA HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. EUROPE HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. MIDDLE EAST HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AFRICA HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASEAN HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GCC HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPEAN UNION HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. BRICS HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. G7 HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. NATO HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. HOSPITAL ACQUIRED INFECTION CONTROL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. HOSPITAL ACQUIRED INFECTION CONTROL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HOSPITAL ACQUIRED INFECTION CONTROL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HEPA FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HEPA FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HEPA FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HEPA FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HEPA FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HEPA FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY IONIZATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY IONIZATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY IONIZATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY IONIZATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY IONIZATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY IONIZATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV AIR PURIFIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV AIR PURIFIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV AIR PURIFIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV AIR PURIFIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV AIR PURIFIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV AIR PURIFIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY BONDED CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY BONDED CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY BONDED CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY BONDED CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY BONDED CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY BONDED CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SILVER COATINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SILVER COATINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SILVER COATINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SILVER COATINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SILVER COATINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SILVER COATINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FOAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FOAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FOAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FOAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FOAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FOAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SOAPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SOAPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SOAPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SOAPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SOAPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SOAPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND WIPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND WIPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND WIPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND WIPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND WIPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND WIPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ETHYLENE OXIDE STERILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ETHYLENE OXIDE STERILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ETHYLENE OXIDE STERILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ETHYLENE OXIDE STERILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ETHYLENE OXIDE STERILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ETHYLENE OXIDE STERILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LOW TEMPERATURE STERILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LOW TEMPERATURE STERILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LOW TEMPERATURE STERILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LOW TEMPERATURE STERILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LOW TEMPERATURE STERILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LOW TEMPERATURE STERILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY RADIATION STERILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY RADIATION STERILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY RADIATION STERILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY RADIATION STERILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY RADIATION STERILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY RADIATION STERILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY STEAM STERILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY STEAM STERILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY STEAM STERILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY STEAM STERILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY STEAM STERILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY STEAM STERILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY VAPORIZED HYDROGEN PEROXIDE STERILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY VAPORIZED HYDROGEN PEROXIDE STERILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY VAPORIZED HYDROGEN PEROXIDE STERILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY VAPORIZED HYDROGEN PEROXIDE STERILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY VAPORIZED HYDROGEN PEROXIDE STERILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY VAPORIZED HYDROGEN PEROXIDE STERILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED DISINFECTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED DISINFECTANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED DISINFECTANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED DISINFECTANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED DISINFECTANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED DISINFECTANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHLORINE BASED DISINFECTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHLORINE BASED DISINFECTANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHLORINE BASED DISINFECTANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHLORINE BASED DISINFECTANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHLORINE BASED DISINFECTANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHLORINE BASED DISINFECTANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEROXYGEN COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEROXYGEN COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEROXYGEN COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEROXYGEN COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEROXYGEN COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEROXYGEN COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY QUATERNARY AMMONIUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY QUATERNARY AMMONIUM COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY QUATERNARY AMMONIUM COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY QUATERNARY AMMONIUM COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY QUATERNARY AMMONIUM COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY QUATERNARY AMMONIUM COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FIXED UV SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FIXED UV SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FIXED UV SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FIXED UV SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FIXED UV SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FIXED UV SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PORTABLE UV DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PORTABLE UV DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PORTABLE UV DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PORTABLE UV DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PORTABLE UV DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PORTABLE UV DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHEMICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHEMICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHEMICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHEMICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHEMICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHEMICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FILTRATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FILTRATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FILTRATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FILTRATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV WATER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV WATER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV WATER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV WATER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV WATER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV WATER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ADULT EMERGENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ADULT EMERGENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ADULT EMERGENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ADULT EMERGENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ADULT EMERGENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ADULT EMERGENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEDIATRIC EMERGENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEDIATRIC EMERGENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEDIATRIC EMERGENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEDIATRIC EMERGENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEDIATRIC EMERGENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEDIATRIC EMERGENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY MEDICAL WARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY MEDICAL WARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY MEDICAL WARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY MEDICAL WARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY MEDICAL WARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY MEDICAL WARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ORTHOPEDIC WARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ORTHOPEDIC WARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ORTHOPEDIC WARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ORTHOPEDIC WARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ORTHOPEDIC WARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ORTHOPEDIC WARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURGICAL WARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURGICAL WARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURGICAL WARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURGICAL WARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURGICAL WARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURGICAL WARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INTENSIVE CARE UNITS, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INTENSIVE CARE UNI